Massive Bio, a cutting-edge AI driven clinical trial matching platform provider, and Foundation Medicine, Inc. today announced a strategic collaboration to increase patient access to cutting edge clinical trials. This collaboration unites Massive Bio’s patient matching technology and last-mile solutions with Foundation Medicine’s global expertise and leadership in next generation sequencing (NGS) and network of healthcare providers.
This partnership seeks to improve the low rate of patient enrollment in oncology clinical trials, which sees only about 8% of eligible patients participating in clinical trials1. As potential new therapies increasingly address rare cancers, approximately 80% of clinical studies globally fail to enroll enough patients with a biopharmaceutical company’s desired timeline, according to a 2020 report published in Perspectives in Clinical Research2. The cornerstone of this partnership lies in integrated solutions that enhance service delivery for both Massive Bio’s and Foundation Medicine’s customers through shared data and AI analytics focused on patient matching.
“The application of real-time AI and our comprehensive data significantly boosts the speed and accuracy of clinical trial matching,” said Dr. Arturo Loaiza-Bonilla, MD MSEd, Co-founder and Chief Medical Officer at Massive Bio. “This capability allows us to provide individualized treatments more quickly and accurately, enhancing patient outcomes across the globe. Joining forces with Foundation Medicine is pivotal as it will allow us to develop solutions to the cancer clinical trial enrollment paradox.”
Massive Bio is building the largest global oncology/hematology network to transform patient recruitment at scale with more than 132,000 patients, 5,000 physicians, 40 pharma and CRO customers and 50 partners. Massive Bio’s real-time, AI-driven platform, Synergy-AI, can analyze and summarize extensive medical records, including biomarker data from multiple sources, to match patients with over 16,000 clinical trials instantly. Massive Bio’s predictive analytics maximizes trial enrollment potential and significantly reduces screen failures.
Through this partnership, Massive Bio and Foundation Medicine hope to increase clinical trial enrollment with their extensive networks and capabilities across the healthcare landscape, employing advanced AI techniques and a robust digital health platform to refine clinical trial processes and enhance precision oncology.
“Beyond providing high quality genomic profiling to support informed decision making, Foundation Medicine is committed to empowering practitioners to act on those decisions by identifying personalized treatment options including clinical trials,” said Heather Jorajuria, Senior Vice President, Clinical ; Scientific Operations at Foundation Medicine. “Through this partnership with Massive Bio, we have the patient at the forefront, leveraging our combined assets and expertise to improve access to clinical trials for patients.”
1 Unger JM Vaidya R Hershman DL, et al.: Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial par
2 Desai.2020 Apr-Jun 2020. Recruitment and retention of participants in clinical studies: Critical Issues and challenges. https://www.ncbi.nlm.nih.gov/
